MINNEAPOLIS, Oct. 13, 2015 /PRNewswire/ -- Venture catalyst Invenshure announces the launch of Tychon Biosciences, a biotechnology company commercializing adaptive immunotherapy technology developed in the laboratory of Dr. Carston (Rick) Wagner at the University of Minnesota.
Dr. Wagner, Professor and Endowed Chair in Medicinal Chemistry at the University of Minnesota and Director of the Chemical Biology Initiative, has developed a novel method to locate and kill specific cancers, utilizing protein-based nanorings, to "re-target" natural immune cells (T-Cells, NK cells). Tychon holds the exclusive right to commercialize intellectual property related to Dr. Wagner's adaptive immunotherapy technology.
Tychon will complete pre-clinical animal studies currently in progress and design and execute manufacturing scale up, clinical trials and first-in-man studies.
"Tychon is buoyed by the meteoric trajectory of adaptive immunotherapy companies developing similar technologies. We believe our technology is very complementary with our peers and offers some real advantages with respect to cost, safety and regulatory and clinical risk," said Danny Cunagin, CEO of Tychon. "We are delighted to partner with Dr. Wagner and his team to commercialize this important technology that could offer significant relief to cancer patients."
"This is our second technology commercialization partnership with Invenshure. We are excited to see the work in Dr. Wagner's lab move toward the clinic, especially in an area of healthcare that could make a real difference in people's lives," said Rebecca Gerber, Marketing Manager for the Office for Technology Commercialization at the University of Minnesota.
Tychon will be announcing several partnerships in the coming months related to its commercialization process.
The company will operate out of Invenshure's offices in Minneapolis until the needs of the organization dictate a transition to a more strategic location.
Invenshure is a venture catalyst that scours university research labs for novel and disruptive technologies ready for commercialization. Invenshure partners with top scientists, physicians, and researchers from the most trusted institutions in healthcare and technology. The company focuses on high-growth sectors including biotech, genomics, healthcare IT, diagnostics, cloud computing technologies, and wireless technologies. For more information, visit http://invenshure.com.
About the Office for Technology Commercialization
The mission of the Office for Technology Commercialization is to facilitate the transfer of University of Minnesota research to licensees for the development of new products and services that benefit the public good, foster economic growth and generate revenue to support the University's research and education mission.
SOURCE Invenshure, LLC